Growth Metrics

Aurinia Pharmaceuticals (AUPH) Income towards Parent Company: 2014-2025

Historic Income towards Parent Company for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Sep 2025 value amounting to $31.6 million.

  • Aurinia Pharmaceuticals' Income towards Parent Company rose 120.53% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 443.39%. This contributed to the annual value of $5.7 million for FY2024, which is 107.36% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Income towards Parent Company of $31.6 million as of Q3 2025, which was up 46.66% from $21.5 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Income towards Parent Company's 5-year high stood at $31.6 million during Q3 2025, with a 5-year trough of -$50.4 million in Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' Income towards Parent Company averaged around $368,545, with its median value being $678,000 (2024).
  • In the last 5 years, Aurinia Pharmaceuticals' Income towards Parent Company crashed by 312.71% in 2021 and then skyrocketed by 3,073.01% in 2025.
  • Aurinia Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$33.3 million in 2021, then rose by 21.84% to -$26.0 million in 2022, then fell by 3.34% to -$26.9 million in 2023, then skyrocketed by 105.47% to $1.5 million in 2024, then soared by 120.53% to $31.6 million in 2025.
  • Its Income towards Parent Company was $31.6 million in Q3 2025, compared to $21.5 million in Q2 2025 and $23.3 million in Q1 2025.